NEWSpublisher 2007 :: AngloChinese Investments
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
from:    to: 
R & D
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » China Biopharmaceuticals Holdings back to previous page show list

China Biopharmaceuticals Holdings

address: Suite 602, China Life Tower,6 Chaowai Street, Chaoyang Dist.
Beijing, China 100020
contact: Tel: 86-10-85251616/85253883
Fax: 86-10-85253882
key person: MAO Peng , MBA Chief Executive Officer (CEO)

AN, Lufan, Chief Operation Officer (COO)

ZHANG, Luyong , Ph.D.Chief Technology Officer (CTO)

LIU, Xiaohao,Vice President Sales

HUANG, Chentai,Chief

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: NO
partner in China: China Pharmaceutical University

SFDA approved: NO


Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
Ingredients: NO
Western Generics: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
Licensed Drugs: NO


China Biopharmaceutical Holdings, Inc (CBH) is a global research driven pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases.

CBH is a U.S. public company with operating subsidiaries in China. CBH takes pride of its strong research, development and manufacturing capabilities and is striving to achieve growth and market leadership through drug commercialization and selective acquisitions of research and manufacturing entities.

Management Team

MAO Peng , MBA Chief Executive Officer (CEO)

AN, Lufan, Chief Operation Officer (COO)Mr. AN Lufan is the President and Chief Operation Officer (COO) of China Biopharmaceutical Holdings (CBH) and the CEO of Nanjing Keyuan Pharmaceutical Technology Corp. Prior to joining Nanjing Keyuan, Mr. An was the CEO of Shandon Tungtai Pharmaceutical Technology Corporation. Mr. An has an extensive experience in research and development and commercialization of new drugs. Mr. An has been involved in the development of at least thirty-two new drugs and published fifteen related articles in international journals. Mr. An graduated from Jining Medical College in 1985 with a B.S. degree in medicine and graduated from China Pharmaceutical University in 1991 with an M.S. degree in Pharmacology.

ZHANG, Luyong , Ph.D.Chief Technology Officer (CTO) Dr. Zhang Luyong is the Chief Technology Officer (CTO) of China Biopharmaceutical Holdings (CBH). He is also a professor and Deputy Director of the technology department of China Pharmaceutical University and a consultant to the National Drugs Examination Committee of China Food and Drug Administration (SFDA). Mr. Zhang founded and was the head of Xinzhung Drug Research and Development Center. He also served as the head of the department of New Drug Examination at China Food and Drug Administration (SFDA) and in this capacity, was invited to lead numerous research projects which were funded by both the government and the private sector. For example, he led the National Laboratory of New Drugs Screening project and established the first national class laboratory in China to be approved by the Ministry of Technology. He also founded Jiangsu New Drugs Screening Center with funding from Jiangsu Province government. Mr. Zhang graduated from China Pharmaceutical University in 1983 with a B.S. degree in Pharmacology and graduated from China Pharmaceutical University in 1989 with a Ph.D. in Pharmacology. He currently holds a professorship at China Pharmaceutical University.

LIU, Xiaohao,Vice President Sales
Mr. Liu Xiaohao is a Senior Vice President of the China Biopharmaceutical Holdings (CBH), in charge of sales operations. Mr. Liu has a strong track record and broad recognition in the drug industry in China. Prior to joining CBH, Mr. Liu held several senior marketing and sales management positions in some of the most powerful companies in the industry. For example, he served as the Vice General Manager of Shanghai Fuxin Pharmaceutical Corp. (" Fuxin "), the largest and among the most successful generic drug manufacturer in China, also listed on Shanghai Stock Exchange. Other prestigious sales management positions that Mr. Liu held were at companies such as: Nanjing Tian-Ying pharmaceutical Corp., Jiangsu Chang Ao Pharmaceutical Corp, Jiangsu Xuzhou Pharmaceutical Corp. Additionally, Mr. Liu organized seminars on various medicine and pharmaceutical topics including the first "National Forum on Narcotics and Intensive Care". Mr. Liu graduated from the SFDA Graduate Research Program in 2002 with M.S. degree in Pharmaceutical Administration and graduated from China Pharmaceutical University in 1986 with M.S. degree in Pharmacology.

HUANG, Chentai,Chief Financial Officer (CFO)
Mr. Huang Chentai is the CFO of China Biopharmaceutical Holdings (CBH); Mr. Huang has more than twenty years of business related experience in North America and Asia and has led numerous public offerings and M&A transactions in Singapore , Taiwan and China . Mr. Huang co-founded and served as a director of Infogroup Investment Corporation in Canada. Mr. Huang graduated from Taiwan Tamkang University in 1971 with a B.A. degree in Business Administration and graduated from Missouri State University in 1979 with an MBA.

Stephen E. Globus, Director
Mr. Stephen Globus is a director of China Biopharmaceutical Holdings (CBH). Mr. Globus was previously the Chairman of Globus Growth Group, a venture capital group for technology companies. Under his management, Globus Growth Group made strategic seed investments in a number of companies such as Plasmaco, a USA manufacturer of plasma TV which was later acquired by Matsushita (Panasonic); Genitope, a San Francisco based biotechnology company in the field of immune-therapies; Proscure, a Boston based biotechnology company which was later acquired by Repligen (RGEN); Kimeragen, a gene modification company which was later acquired by Valigen .Other early investments of Globus Growth Group are in FuelCellEnergy (FCEL) and ExSar. Mr. Globus mainly resides in New York City. 

Subsidiaries-Nanjing Keyuan
Nanjing Keyuan is one of China’s leading drug research and development companies with a demonstrated ability to develop and to obtain SFDA approval for an average of three to five drugs annually.

Keyuan has developed twenty four major new drugs in the past three years and has obtained SFDA approvals for sixteen of the drugs. The rest of Keyuan's drugs are undergoing various phases of clinical trials towards approval by the SFDA.

As a subsidiary of China Biopharmaceuticals Holdings, Inc., Keyuan intends to use CBH manufacturing and marketing capabilities and graduatlly move towards full, in-house commercialization of its drug products. CBH has the right of first refusal for developing and manufacturing Keyuan's drug products and/or other research findings.

Keyuan employs top scientists with expertise in the fields of pharmaceutics, pharmacology, toxicology, organic chemistry, medicine and traditional chinese medicine. Many of the scientists have been involved in new drug research in China Pharmaceutical University and in other large domestic research institutions
A Joint Venture Drug Development Center with China Pharmaceutical University

The Company
formed a joint laboratory and collaborates with China Pharmaceutical University in different aspects of drug research and development. The joint laboratory gives the company access to new drug projects and obtains the right of first refusal to choose from the results of such projects for further development.

The University is one of the most accredited and comprehensive pharmaceutical research institutions in China and as such. As a partner of the University, they have the right to utilize, free of charge, the University's advanced lab instruments and sophisticated equipment. Additionally, they use the Center to conduct pre-clinical tests for toxicity and efficacy. They formed strong relationships with the University's alumni who provide an important network of decision makers and key players in the pharmaceutical industry in China.

Mr. MAO Peng is the Chairman and Chief Executive Officer (CEO) of China Biopharmaceutical Holdings (CBH).Prior to founding CBH, Mr. Mao was the CEO of China Pharmaceuticals Investment Fund and managed the fund's investments in the pharmaceutical industry in China . Mr. Mao was also the co-founder and president of Infogroup Investment Corp., a Canadian company specializing in corporate finance and investment management. Mr. Mao graduated from Shandong University in 1993 with a B.A. degree in Marketing and graduated from the Lundquist College of Business at the University of Oregon in 1997 with an MBA degree.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.